Daclizumab Subcutaneous and Insulin Degludec (U-100) Vials
Determining the interaction of Daclizumab Subcutaneous and Insulin Degludec (U-100) Vials and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: daclizumab
Brand name: Zinbryta, Zenapax
Synonyms: Daclizumab
Generic Name: insulin degludec
Brand name: Tresiba, Tresiba FlexTouch
Synonyms: Insulin degludec, Insulin Degludec
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Daclizumab Subcutaneous-Insulin Degludec (U-200) Prefilled Pens
- Daclizumab Subcutaneous-Insulin degludec and liraglutide
- Daclizumab Subcutaneous-Insulin degludec and liraglutide Subcutaneous
- Daclizumab Subcutaneous-Insulin degludec Subcutaneous
- Daclizumab Subcutaneous-Insulin detemir
- Daclizumab Subcutaneous-Insulin Detemir (Cartridges and Prefilled Syringes)
- Insulin Degludec (U-100) Vials-Dacogen
- Insulin Degludec (U-100) Vials-Dacomitinib
- Insulin Degludec (U-100) Vials-Dactinomycin
- Insulin Degludec (U-100) Vials-Dactinomycin Injection
- Insulin Degludec (U-100) Vials-Dactinomycin Intravenous
- Insulin Degludec (U-100) Vials-Daklinza